Transition from secukinumab to adalimumab in COVID-19-induced psoriasis flare-up treatment: A case report
Description
Coronavirus disease 2019 (COVID-19) is known to trigger systemic inflammation and elicit immune responses, which may disrupt the delicate balance of cytokines involved in psoriatic regulation. Compared to other therapies in dermatology, biologics
